Page 2 - Partial Response News Today

FOSTER CITY, Calif., Oct. 26, 2023 -- Apollomics Inc. , today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with...

– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR –

Jayme Heim, MSN, FNP-BC; and Lauren Miller, MPAS, PA-C, share thoughts on the use of oral systemic and biologic treatments in plaque psoriasis, commenting on the need for personalized care for patients.

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

GVHD experts outline the treatment options for patients with steroid-refractory chronic GVHD.

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment.

Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for... | June 5, 2023

Hisashi Kobayashi, whose steady leadership as dean guided Princeton's School of Engineering and Applied Science through a rapid expansion of programs and facilities in the late 1980s and early 1990s, died on March 9. He was 84.

Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.